The upcoming data release represents a pivotal milestone for the biopharmaceutical firm as it seeks to establish Axpaxli as a primary option for patients suffering from wet AMD. According to the company, the Phase 3 superiority trial is designed to demonstrate the drug's clinical advantages over existing therapies. Investors reacted sharply to the news, pushing the stock price to $10.25 during late-day trading.

Clinical Timeline and Presentation

While the initial topline findings arrive on Tuesday, the company plans to provide a more comprehensive breakdown of the results later this month. Detailed clinical data will be presented at the Macula Society annual meeting, scheduled for Feb. 25-28. This presentation is expected to offer deeper insights into the safety profile and long-term efficacy of the treatment.

The 15% rally reflects high expectations for the drug's performance in a competitive ophthalmology market. If the Phase 3 data meets its primary endpoints, Ocular Therapeutix could be positioned to capture significant market share from established injectable treatments for macular degeneration.